McKesson Corporation $MCK Stock Acquired by Kestra Advisory Services LLC

Kestra Advisory Services LLC lifted its position in McKesson Corporation (NYSE:MCK) by 13.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 30,595 shares of the company’s stock after buying an additional 3,623 shares during the period. Kestra Advisory Services LLC’s holdings in McKesson were worth $26,122,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MCK. BlackRock Inc. bought a new stake in shares of McKesson during the second quarter valued at approximately $8,156,743,000. Bank of America Corp DE lifted its position in McKesson by 2.4% in the 1st quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock valued at $1,331,552,000 after acquiring an additional 35,916 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in McKesson by 3.3% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company’s stock valued at $697,096,000 after purchasing an additional 29,747 shares during the last quarter. Legal & General Group Plc purchased a new stake in McKesson during the 2nd quarter valued at $656,566,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of McKesson in the 2nd quarter worth $651,462,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Insider Buying and Selling

In other McKesson news, EVP Francisco Fraga sold 650 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $1,102.96, for a total value of $716,924.00. Following the transaction, the executive vice president owned 4,414 shares of the company’s stock, valued at approximately $4,868,465.44. This represents a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the transaction, the chief accounting officer directly owned 521 shares in the company, valued at $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,462 shares of company stock valued at $2,511,106 over the last 90 days. Company insiders own 0.06% of the company’s stock.

McKesson Trading Down 1.0%

Shares of MCK stock opened at $1,060.79 on Friday. McKesson Corporation has a 12-month low of $723.68 and a 12-month high of $1,121.50. The stock has a market capitalization of $122.48 billion, a P/E ratio of 27.28, a P/E/G ratio of 2.08 and a beta of 0.27. The firm’s 50 day moving average is $938.13 and its 200 day moving average is $868.12.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. The business had revenue of $110.96 billion during the quarter, compared to analyst estimates of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 202.94%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the business earned $9.86 EPS. As a group, equities analysts predict that McKesson Corporation will post 46.21 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is 9.67%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MCK. Wells Fargo & Company boosted their price target on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 11th. Leerink Partners increased their price objective on McKesson from $1,070.00 to $1,200.00 and gave the company an “outperform” rating in a research report on Thursday. Morgan Stanley set a $977.00 price objective on McKesson in a report on Tuesday, October 6th. Wall Street Zen raised McKesson from a “hold” rating to a “buy” rating in a research report on Saturday, October 17th. Finally, Royal Bank Of Canada boosted their target price on McKesson from $845.00 to $965.00 and gave the stock a “sector perform” rating in a research report on Thursday. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,026.18.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.